Kazia Therapeutics (KZIA) Convertible Debt (2019 - 2021)

Kazia Therapeutics has reported Convertible Debt for 3 years, with the latest figure at $1.9 million in Q4 2021.

• For the quarter ending Q4 2021, Convertible Debt fell 20.22% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2021 stood at $1.9 million (down 20.22% YoY), and the FY2021 full-year result was $2.3 million, up 0.82% from the prior year.
• Convertible Debt for Q4 2021 stood at $1.9 million, down from $2.3 million in the prior quarter.
• The five-year high for Convertible Debt was $2.6 million in Q2 2019, with the low at $1.9 million in Q4 2021.
• Historically, Convertible Debt has averaged $2.3 million across 3 years, with a median of $2.3 million in 2021.
• The largest YoY upside for Convertible Debt was 0.82% in 2021 against a maximum downside of 20.22% in 2021.
• Kazia Therapeutics' Convertible Debt stood at $2.4 million in 2019, then declined by 1.97% to $2.4 million in 2020, then retreated by 20.22% to $1.9 million in 2021.
• The last three Convertible Debt figures came in at $1.9 million (Q4 2021), $2.3 million (Q2 2021), and $2.4 million (Q4 2020), per Business Quant data.